Abnormal angiogenesis in diabetes mellitus

The adverse long‐term effects of diabetes mellitus have been well described and involve many organ systems. While diabetes management has largely focused on control of hyperglycemia, the presence of abnormalities of angiogenesis may cause or contribute to many of the clinical manifestations of diabetes. When compared with non‐diabetic subjects, diabetics demonstrate vascular abnormalities of the retina, kidneys, and fetus. Diabetics have impaired wound healing, increased risk of rejection of transplanted organs, and impaired formation of coronary collaterals. In each of these conditions, and possibly in diabetic neuropathy as well, abnormalities of angiogenesis can be implicated in the pathogenesis. A perplexing feature of the aberrant angiogenesis is that excessive and insufficient angiogenesis can occur in different organs in the same individual. In this review, the clinical features, molecular mechanisms, and potential therapeutic options of abnormal angiogenesis in diabetes will be reviewed. © 2002 Wiley Periodicals, Inc. Med Res Rev, 23, No. 2, 117–145, 2003

[1]  M. Cotter,et al.  Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats , 2004, Diabetologia.

[2]  T. Hostetter Prevention of end-stage renal disease due to type 2 diabetes. , 2001, The New England journal of medicine.

[3]  J. Garb,et al.  Basic fibroblast growth factor stimulates angiogenesis in the hindlimb of hyperglycemic rats. , 1998, The Journal of surgical research.

[4]  J. Waltenberger,et al.  Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. , 2000, Circulation.

[5]  P. Thuluvath,et al.  Outcome of liver transplantation in patients with diabetes mellitus: A case‐control study , 2001 .

[6]  S. Nussey,et al.  Synthesis of NG, NG Dimethylarginine by Human Endothelial Cells , 1993 .

[7]  M. Haneda,et al.  Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  A. Abacı,et al.  Effect of diabetes mellitus on formation of coronary collateral vessels. , 1999, Circulation.

[9]  M. Cotter,et al.  Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic ratsand nerve function , 1993, Diabetologia.

[10]  D. Cheresh,et al.  Cell adhesion and angiogenesis. , 1996, Trends in cell biology.

[11]  J. Isner,et al.  Therapeutic Angiogenesis for Coronary Artery Disease , 2002, Annals of Internal Medicine.

[12]  D. Stewart,et al.  Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. , 1998, Circulation research.

[13]  M. Cotter,et al.  Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. , 1995, The Journal of clinical investigation.

[14]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Rand Recent advances in diabetic retinopathy. , 1981, The American journal of medicine.

[16]  P. Sloan,et al.  The effect of streptozotocin-induced experimental diabetes mellitus on calvarial defect healing and bone turnover in the rat. , 2001, International journal of oral and maxillofacial surgery.

[17]  G. Schatteman,et al.  Angiogenesis: New insights and therapeutic potential , 2000, The Anatomical record.

[18]  M. Longaker,et al.  Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. , 1995, The Journal of Biological Chemistry.

[19]  J. Tooke,et al.  Aetiology of Diabetic Foot Ulceration: A Role for the Microcirculation? , 1992, Diabetic medicine : a journal of the British Diabetic Association.

[20]  M. Grant,et al.  Neovascular growth factors , 1991, Eye.

[21]  M. Roberts,et al.  Distribution of systemically administered ampicillin, benzylpenicillin, and flucloxacillin in excisional wounds in diabetic and normal rats and effects of local topical vasodilator treatment , 1996, Antimicrobial agents and chemotherapy.

[22]  E S Gragoudas,et al.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.

[23]  S. Bonner-Weir,et al.  Beneficial Influence of Glycemic Control Upon the Growth and Function of Transplanted Islets , 1994, Diabetes.

[24]  S. Bonner-Weir,et al.  Vulnerability of Islets in the Immediate Posttransplantation Period: Dynamic Changes in Structure and Function , 1996, Diabetes.

[25]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[26]  A. Balamurugan,et al.  Successful Subcutaneous Pancreatic Islet Transplantation Using an Angiogenic Growth Factor–Releasing Device , 2001, Pancreas.

[27]  C. Dafogianni,et al.  Serum Angiogenin Levels in Children and Adolescents with Insulin-Dependent Diabetes Mellitus , 1998, Pediatric Research.

[28]  E. Reece,et al.  Multifactorial basis of the syndrome of diabetic embryopathy. , 1996, Teratology.

[29]  J. Mestan,et al.  Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. , 1999, Pharmacology & therapeutics.

[30]  S. Kagami,et al.  Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. , 1994, The Journal of clinical investigation.

[31]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[32]  S. Bursell,et al.  Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.

[33]  Z. Makita,et al.  Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.

[34]  M. Serio,et al.  Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.

[35]  R. Frank Vascular endothelial growth factor--its role in retinal vascular proliferation. , 1994, The New England journal of medicine.

[36]  A. Rose,et al.  Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material , 1992, The Journal of pathology.

[37]  M. Bitar,et al.  Transforming growth factor-beta and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. , 1996, The Journal of surgical research.

[38]  A. Barden,et al.  Advanced Glycation End Products: A Review , 2013 .

[39]  J P Cooke,et al.  The Pathophysiology of Peripheral Arterial Disease: Rational Targets for Drug Intervention , 1997, Vascular medicine.

[40]  K. Suzuma,et al.  Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. , 2000, Investigative ophthalmology & visual science.

[41]  J. Ware,et al.  Inhibition of Protein Kinase C&agr; Prevents Endothelial Cell Migration and Vascular Tube Formation In Vitro and Myocardial Neovascularization In Vivo , 2002, Circulation research.

[42]  S. Moncada,et al.  Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis , 1992, Journal of cardiovascular pharmacology.

[43]  B. Avcı,et al.  Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. , 2000, Clinical biochemistry.

[44]  D. Greene,et al.  Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. , 2000, Diabetes.

[45]  J. Eng,et al.  Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. , 1996, The Journal of clinical endocrinology and metabolism.

[46]  K. Alitalo,et al.  Vascularization of the mouse embryo: A study of flk‐1, tek, tie, and vascular endothelial growth factor expression during development , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[47]  I. Buschmann,et al.  Collateral circulation and diabetes. , 1999, Circulation.

[48]  K Messmer,et al.  Angiogenesis and Hemodynamics of Microvasculature of Transplanted Islets of Langerhans , 1989, Diabetes.

[49]  J. Ronan,et al.  Acidic fibroblast growth factor accelerates dermal wound healing in diabetic mice. , 1995, The Journal of investigative dermatology.

[50]  M. Blagosklonny,et al.  UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response , 1998, Invasion and Metastasis.

[51]  J. Nyengaard,et al.  The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes , 1993, Diabetologia.

[52]  L. Aiello,et al.  Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.

[53]  P. Cryer,et al.  Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus. , 1982, The Journal of clinical investigation.

[54]  Y. Mori,et al.  Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. , 2001, Circulation research.

[55]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[56]  J. Cheigh,et al.  Kidney Transplantation in Patients with Type 1 Diabetes Mellitus: Long-Term Prognosis for Patients and Grafts , 2001, The Korean journal of internal medicine.

[57]  G. Lip,et al.  Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. , 2000, Investigative ophthalmology & visual science.

[58]  P Lavie,et al.  Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. , 1999, Circulation.

[59]  M. Caliari,et al.  Aminoguanidine Prevents Impaired Healing and Deficient Angiogenesis in Diabetic Rats , 1999, Inflammation.

[60]  K. Takeuchi,et al.  Impaired healing of gastric lesions in streptozotocin-induced diabetic rats: effect of basic fibroblast growth factor. , 1997, The Journal of pharmacology and experimental therapeutics.

[61]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.

[62]  E. Manseau,et al.  Vascular permeability factor mRNA and protein expression in human kidney. , 1992, Kidney international.

[63]  B. Spiegelman,et al.  Vasodilation of rat retinal microvessels induced by monobutyrin. Dysregulation in diabetes. , 1993, The Journal of clinical investigation.

[64]  G. Kouvaras,et al.  Comparison of coronary collateral circulation in diabetic and nondiabetic patients suffering from coronary artery disease , 1999, Clinical cardiology.

[65]  B. Brenner,et al.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.

[66]  R. Tilton,et al.  Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes Materials and Methods Laboratory Animals , 2022 .

[67]  A. Sommer,et al.  Recombinant basic fibroblast growth factor accelerates wound healing. , 1988, The Journal of surgical research.

[68]  M Linet,et al.  Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.

[69]  G. Lutty,et al.  Localization of vascular endothelial growth factor in human retina and choroid. , 1996, Archives of ophthalmology.

[70]  S. Bode-Böger,et al.  Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. , 1996, Biochemical and biophysical research communications.

[71]  R. McCarter,et al.  Maternal diabetes and cardiovascular malformations: predominance of double outlet right ventricle and truncus arteriosus. , 1990, Teratology.

[72]  R. Kronmal,et al.  Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry). , 1994, The American journal of cardiology.

[73]  S. P. Andrade,et al.  Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. , 1999, Life sciences.

[74]  G. Wu,et al.  Arginine nutrition and cardiovascular function. , 2000, The Journal of nutrition.

[75]  M. Cooper,et al.  Vascular changes in the diabetic kidney: effects of ACE inhibition. , 1995, Journal of diabetes and its complications.

[76]  K. Blennow,et al.  The Role of the Polymorphic Genes Apolipoprotein E and Methylene- tetrahydrofolate Reductase in the Development of Dementia of the Alzheimer Type , 1999, Dementia and Geriatric Cognitive Disorders.

[77]  J. Waltenberger Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. , 2001, Cardiovascular research.

[78]  Liying Sun,et al.  Transfection with aFGF cDNA improves wound healing. , 1997, The Journal of investigative dermatology.

[79]  M. Grant,et al.  Fibronectin Fragments Modulate Human Retinal Capillary Cell Proliferation and Migration , 1998, Diabetes.

[80]  M. Nattrass,et al.  Insulin Resistance: a Multifaceted Metabolic Syndrome. Insights Gained Using a Low‐dose Insulin Infusion Technique , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[81]  I. Hirsch,et al.  Higher Glycemic Thresholds for Symptoms During β-Adrenergic Blockade in IDDM , 1991, Diabetes.

[82]  A. Patz Clinical and experimental studies on retinal neovascularization. XXXIX Edward Jackson Memorial Lecture. , 1982, American journal of ophthalmology.

[83]  D. Loskutoff,et al.  Tissue factor gene expression in the adipose tissues of obese mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[84]  H. Gröne,et al.  Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. , 1998, Journal of the American Society of Nephrology : JASN.

[85]  Y. Marcel,et al.  Apolipoprotein A-I Conformation in Reconstituted Discoidal Lipoproteins Varying in Phospholipid and Cholesterol Content (*) , 1995, The Journal of Biological Chemistry.

[86]  Yukitaka Shizukuda,et al.  Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. , 1999, Circulation research.

[87]  P. Reitz,et al.  Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-α, TGF-β, bFGF and Vimentin) in cultured and transplanted rat islets , 2000, Diabetologia.

[88]  J. R. Mekkes,et al.  Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation , 1999, Archives of Dermatological Research.

[89]  Y. Kaneda,et al.  Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. , 1996, Kidney international.

[90]  G. Jerums,et al.  Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes , 2000, Diabetologia.

[91]  S. Homma,et al.  Acute Elevations of Plasma Asymmetric Dimethylarginine and Impaired Endothelial Function in Response to a High-Fat Meal in Patients With Type 2 Diabetes , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[92]  J. Cooke,et al.  Does ADMA cause endothelial dysfunction? , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[93]  E. Middelkoop,et al.  Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. , 1998, The Journal of investigative dermatology.

[94]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[95]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[96]  D. Cucinotta,et al.  Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. , 2001, Diabetes.

[97]  B. Williams A Potential Role for Angiotensin II-Induced Vascular Endothelial Growth Factor Expression in the Pathogenesis of Diabetic Nephropathy? , 1998, Mineral and Electrolyte Metabolism.

[98]  C. Kilo,et al.  Diabetes-induced increases in vascular permeability and changes in granulation tissue levels of sorbitol, myo-inositol, chiro-inositol, and scyllo-inositol are prevented by sorbinil. , 1986, Metabolism: clinical and experimental.

[99]  J. Cooke,et al.  Angiogenesis Is Impaired by Hypercholesterolemia: Role of Asymmetric Dimethylarginine , 2000, Circulation.

[100]  M. Dewhirst,et al.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.

[101]  H. Hammes,et al.  Integrin Chatter and Vascular Function in Diabetic Retinopathy , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[102]  R. Natarajan,et al.  A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. , 1996, The Journal of clinical endocrinology and metabolism.

[103]  D. Cockroft,et al.  Teratogenic effects of excess glucose on head-fold rat embryos in culture. , 1977, Teratology.

[104]  L. Baker,et al.  Diabetic embryopathy: a selective review of recent trends. , 1993, Journal of diabetes and its complications.

[105]  B. Spiegelman PPARγ in Monocytes: Less Pain, Any Gain? , 1998, Cell.

[106]  E. Van Obberghen,et al.  Regulation of Vascular Endothelial Growth Factor Expression by Advanced Glycation End Products* , 2001, The Journal of Biological Chemistry.

[107]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[108]  G. Wolf,et al.  Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. , 1992, The American journal of pathology.

[109]  M. Cooper,et al.  Role of Endothelium-Derived Nitric Oxide in the Pathogenesis of the Renal Hemodynamic Changes of Experimental Diabetes , 1994, Diabetes.

[110]  O. Carpén,et al.  Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. , 2001, Molecular human reproduction.

[111]  J. Isner,et al.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. , 1999, The American journal of pathology.

[112]  L. Aiello,et al.  Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. , 1996, The Journal of clinical investigation.

[113]  D. Charnock-Jones,et al.  Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. , 1996, Human reproduction.

[114]  M. Cotter,et al.  Effects of the diacylglycerol complexing agent, cremophor, on nerve-conduction velocity and perfusion in diabetic rats. , 1999, Journal of diabetes and its complications.

[115]  Y. Wang,et al.  Hyperglycemia-induced vasculopathy in the murine vitelline vasculature: correlation with PECAM-1/CD31 tyrosine phosphorylation state. , 1999, The American journal of pathology.

[116]  R. Zatz,et al.  Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. , 1996, Nephron.

[117]  Peipei Ping,et al.  Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heart , 1996, Nature Medicine.

[118]  J. Styrud,et al.  Diabetic Embryopathy Studies With Animal and In Vitro Models , 1991, Diabetes.

[119]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[120]  B. Gallacher,et al.  Glucose-Induced Protein Kinase C Activation Regulates Vascular Permeability Factor mRNA Expression and Peptide Production by Human Vascular Smooth Muscle Cells In Vitro , 1997, Diabetes.

[121]  C. Léránth,et al.  Yolk sac failure in embryopathy due to hyperglycemia: ultrastructural analysis of yolk sac differentiation associated with embryopathy in rat conceptuses under hyperglycemic conditions. , 1986, Teratology.

[122]  P. Tsao,et al.  Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. , 1998, Circulation.

[123]  D. Harrison,et al.  Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[124]  A. Hartner,et al.  J Am Soc Nephrol 11: 71–79, 2000 Nitric Oxide Synthase Isoforms and Glomerular Hyperfiltration in Early Diabetic Nephropathy , 2022 .

[125]  J. Pfeilschifter,et al.  Expressional Regulation of Angiopoietin-1 and -2 and the Tie-1 and -2 Receptor Tyrosine Kinases during Cutaneous Wound Healing: A Comparative Study of Normal and Impaired Repair , 2001, Laboratory Investigation.

[126]  J. Williamson,et al.  Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. , 2001 .

[127]  Z. Makita,et al.  Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.

[128]  C. Kilo,et al.  Sorbinil Prevents Diabetes-induced Increases in Vascular Permeability But Does Not Alter Collagen Cross-Linking , 1985, Diabetes.

[129]  A. Joly,et al.  Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. , 2001, Endocrinology.

[130]  L. Gnudi,et al.  Interaction of Angiotensin Ii and Mechanical Stretch on Vascular Endothelial Growth Factor Production by Human Mesangial Cells , 2022 .

[131]  G. Steil,et al.  GENE EXPRESSION OF VEGF AND ITS RECEPTORS Flk-1/KDR AND Flt-1 IN CULTURED AND TRANSPLANTED RAT ISLETS1 , 2001, Transplantation.

[132]  O. Korsgren,et al.  Effects of Hyperglycemia on Function of Isolated Mouse Pancreatic Islets Transplanted Under Kidney Capsule , 1989, Diabetes.

[133]  D. Birnbaum,et al.  Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. , 1996, Genomics.

[134]  K. Sharma,et al.  Hyperglycemia and Diabetic Kidney Disease: The Case for Transforming Growth Factor–β as a Key Mediator , 1995, Diabetes.

[135]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[136]  Timothy McCaffrey,et al.  A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation , 2001, Nature Medicine.

[137]  K. Preissner,et al.  Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. , 1995, Experimental eye research.

[138]  M. Cooper,et al.  Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.

[139]  D. Cucinotta,et al.  Raxofelast, a hydrophilic vitamin E-like antioxidant, stimulates wound healing in genetically diabetic mice. , 2001, Surgery.

[140]  H. Itoh,et al.  Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. , 1993, The Journal of clinical investigation.

[141]  G. King,et al.  Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. , 1997, Journal of the American Society of Nephrology : JASN.

[142]  D. C. Han,et al.  Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. , 2000, American journal of physiology. Renal physiology.

[143]  M. Cotter,et al.  Essential Fatty Acid Diet Supplementation: Effects on Peripheral Nerve and Skeletal Muscle Function and Capillarization in Streptozocin-Induced Diabetic Rats , 1991, Diabetes.